Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)
China · Delayed Price · Currency is CNY 3.090
+0.010 (0.32%)
Oct 28, 2026, 1:15 PM CST
SHE:300026 Revenue
Tianjin Chase Sun Pharmaceutical Co.,Ltd had revenue of 1.06B CNY in the quarter ending June 30, 2026, a decrease of -24.57%. This brings the company's total for the last twelve months to 4.33B, down -22.35% year-over-year. In the year 2025, Tianjin Chase Sun Pharmaceutical Co.,Ltd had annual revenue of 4.94B, down -14.55%. That makes Tianjin Chase Sun Pharmaceutical Co.,Ltd the 9,759th largest company in the world by revenue and 1,567th in China.
Revenue (ttm)
4.33B
Revenue Growth
-22.35%
P/S Ratio
2.13
Revenue / Employee
893.26K
Employees
4,852
Market Cap
9.28B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:300026 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.94B | -841.64M | -14.55% |
| Dec 31, 2024 | 5.78B | -326.09M | -5.34% |
| Dec 31, 2023 | 6.11B | -541.17M | -8.14% |
| Jan 1, 2023 | 6.65B | -1.02B | -13.30% |
| Dec 31, 2021 | 7.67B | 1.18B | 18.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.